Indefinite Delivery Contract SPE2DR25D9353

The Defense Logistics Agency (DLA) awarded a single-award Indefinite Delivery Contract (IDC) valued at $4,999,999 to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide pharmaceutical products and medical supplies to support the Department of Defense (DoD) and other federal agencies. The IDC contract, valid through December 2026, covers a wide range of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications.

This IDC is part of the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) acquisition, which aims to establish multiple prime vendor contracts to provide worldwide pharmaceutical support to DoD customers, the U.S. Coast Guard, and other government agencies. The PPV-G GEN V solicitation, expected to be issued in March 2024, will have a total estimated value of $30.3 billion and will be awarded on a regional basis, with at least three different contractors selected across the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet line items. The contracts will have a 30-month base period and three 30-month option periods, and awards will be made on a lowest price technically acceptable (LPTA) basis.